Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GlaxoSmithKline
National Cancer Institute (NCI)
NRG Oncology
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Artios Pharma Ltd
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Sun Yat-sen University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
M.D. Anderson Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Continuity Biosciences, LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
University of California, San Francisco
AstraZeneca
Bristol-Myers Squibb
Hoffmann-La Roche
Gilead Sciences
Genmab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Incyte Corporation
First Affiliated Hospital of Guangxi Medical University
Centre Oscar Lambret
AstraZeneca
AstraZeneca
City of Hope Medical Center
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Revolution Medicines, Inc.
Merck Sharp & Dohme LLC